GSK files for European approval of diabetes drug
Research Triangle Park, N.C. —
Albiglutide, which will go by the name Eperzan, is an investigational injectible treatment for adults with type 2 diabetes. The drug is expected to compete against other injectible diabetes drugs, including Novo Nordisk’s daily injectible drug Victoza. GSK expects its once-weekly albiglutide will offer a dosing advantage.
Albiglutide was discovered and developed by Human Genome Sciences, which partnered with GSK on the compound. GSK last year acquired Human Genome Sciences in a $3.6 billion takeover. The compound is not not yet approved anywhere in the world but the drug maker has already taken steps to secure U.S. approval. GSK made its albiglutide regulatory filing to the Food and Drug Administration in January.
London-based GSK operates its U.S. headquarters in Research Triangle Park.
Please Log In to add a comment.
Best of TechWire Insider
- From photos to out-of-this-world art: Raleigh firm's software transforms images
- LabCorp expands gene tests for cancer - but don't confuse these with 23andMe
- ChannelAdvisor: Mobile cuts deeply into PC share of online shopping
- Inside Appia's latest funding deal: Debt beats dilution
- Can Barley's bark win Super Bowl gold for Durham startup?
- Tech guru Mossberg changes gears, praises Republic Wireless
- Survey explodes myth of the poor VC-backed entrepreneur
- Analyze this: SAS steps up education commitment with Teradata deal
- Web Foundation report reflects concerns about US security state
- IBM bashes Bridgestone after tire giant sues for $600M